PRESSEMITTEILUNGEN

Ingelheim, Germany (ots/PRNewswire) – Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], for its efficacy [...]

Continue reading

Angiogenesis, Angiogenic, Bibf, Blood Vessels, Boehringer Ingelheim, Du Bois, Good Experience, Group Germany, Harter, Intergroup Study, International Consortium, Md Phd, New Blood, Novel Agents, Oral Compound, Ovarian Cancer, Phase Iii, Prnewswire, Study Group, Tumours